Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

DEK depletion negatively regulates Rho/ROCK/MLC pathway in non-small cell lung cancer.

Wang J, Sun L, Yang M, Luo W, Gao Y, Liu Z, Qiu X, Wang E.

J Histochem Cytochem. 2013 Jul;61(7):510-21. doi: 10.1369/0022155413488120. Epub 2013 Apr 9.

2.

E-cadherin negatively regulates neoplastic growth in non-small cell lung cancer: role of Rho GTPases.

Asnaghi L, Vass WC, Quadri R, Day PM, Qian X, Braverman R, Papageorge AG, Lowy DR.

Oncogene. 2010 May 13;29(19):2760-71. doi: 10.1038/onc.2010.39. Epub 2010 Mar 15.

3.

E1AF/PEA3 activates the Rho/Rho-associated kinase pathway to increase the malignancy potential of non-small-cell lung cancer cells.

Hakuma N, Kinoshita I, Shimizu Y, Yamazaki K, Yoshida K, Nishimura M, Dosaka-Akita H.

Cancer Res. 2005 Dec 1;65(23):10776-82.

4.

Deleted in liver cancer 1 (DLC1) negatively regulates Rho/ROCK/MLC pathway in hepatocellular carcinoma.

Wong CC, Wong CM, Ko FC, Chan LK, Ching YP, Yam JW, Ng IO.

PLoS One. 2008 Jul 23;3(7):e2779. doi: 10.1371/journal.pone.0002779.

5.

Increase in cell motility by carbon ion irradiation via the Rho signaling pathway and its inhibition by the ROCK inhibitor Y-27632 in lung adenocarcinoma A549 cells.

Murata K, Noda SE, Oike T, Takahashi A, Yoshida Y, Suzuki Y, Ohno T, Funayama T, Kobayashi Y, Takahashi T, Nakano T.

J Radiat Res. 2014 Jul;55(4):658-64. doi: 10.1093/jrr/rru002. Epub 2014 Mar 21.

6.
7.

ANLN plays a critical role in human lung carcinogenesis through the activation of RHOA and by involvement in the phosphoinositide 3-kinase/AKT pathway.

Suzuki C, Daigo Y, Ishikawa N, Kato T, Hayama S, Ito T, Tsuchiya E, Nakamura Y.

Cancer Res. 2005 Dec 15;65(24):11314-25.

8.

PRL-3 facilitates angiogenesis and metastasis by increasing ERK phosphorylation and up-regulating the levels and activities of Rho-A/C in lung cancer.

Ming J, Liu N, Gu Y, Qiu X, Wang EH.

Pathology. 2009 Feb;41(2):118-26. doi: 10.1080/00313020802579268.

PMID:
19152186
9.

DEK oncoprotein regulates transcriptional modifiers and sustains tumor initiation activity in high-grade neuroendocrine carcinoma of the lung.

Shibata T, Kokubu A, Miyamoto M, Hosoda F, Gotoh M, Tsuta K, Asamura H, Matsuno Y, Kondo T, Imoto I, Inazawa J, Hirohashi S.

Oncogene. 2010 Aug 19;29(33):4671-81. doi: 10.1038/onc.2010.217. Epub 2010 Jun 14.

PMID:
20543864
10.

High expression of oncoprotein DEK predicts poor prognosis of small cell lung cancer.

Wang X, Lin L, Ren X, Lin Z, Li Z, Li C, Jin T.

Int J Clin Exp Pathol. 2014 Jul 15;7(8):5016-23. eCollection 2014.

11.

Vincristine enhances amoeboid-like motility via GEF-H1/RhoA/ROCK/Myosin light chain signaling in MKN45 cells.

Eitaki M, Yamamori T, Meike S, Yasui H, Inanami O.

BMC Cancer. 2012 Oct 12;12:469. doi: 10.1186/1471-2407-12-469.

12.

PKC-β exacerbates in vitro brain barrier damage in hyperglycemic settings via regulation of RhoA/Rho-kinase/MLC2 pathway.

Srivastava K, Shao B, Bayraktutan U.

J Cereb Blood Flow Metab. 2013 Dec;33(12):1928-36. doi: 10.1038/jcbfm.2013.151. Epub 2013 Aug 21.

13.

miR-146a inhibits cell growth, cell migration and induces apoptosis in non-small cell lung cancer cells.

Chen G, Umelo IA, Lv S, Teugels E, Fostier K, Kronenberger P, Dewaele A, Sadones J, Geers C, De Grève J.

PLoS One. 2013;8(3):e60317. doi: 10.1371/journal.pone.0060317. Epub 2013 Mar 26.

14.

The human DEK oncogene stimulates β-catenin signaling, invasion and mammosphere formation in breast cancer.

Privette Vinnedge LM, McClaine R, Wagh PK, Wikenheiser-Brokamp KA, Waltz SE, Wells SI.

Oncogene. 2011 Jun 16;30(24):2741-52. doi: 10.1038/onc.2011.2. Epub 2011 Feb 14.

15.

Downregulation of KPNA2 in non-small-cell lung cancer is associated with Oct4 expression.

Li XL, Jia LL, Shi MM, Li X, Li ZH, Li HF, Wang EH, Jia XS.

J Transl Med. 2013 Sep 26;11:232. doi: 10.1186/1479-5876-11-232.

16.

Role of RhoA and its effectors ROCK and mDia1 in the modulation of deformation-induced FAK, ERK, p38, and MLC motogenic signals in human Caco-2 intestinal epithelial cells.

Chaturvedi LS, Marsh HM, Basson MD.

Am J Physiol Cell Physiol. 2011 Nov;301(5):C1224-38. doi: 10.1152/ajpcell.00518.2010. Epub 2011 Aug 17.

17.

Expression of HAb18G in non-small lung cancer and characterization of activation, migration, proliferation, and apoptosis in A549 cells following siRNA-induced downregulation of HAb18G.

Xu X, Liu S, Lei B, Li W, Lin N, Sheng W, Huang A, Shen H.

Mol Cell Biochem. 2013 Nov;383(1-2):1-11. doi: 10.1007/s11010-013-1722-7. Epub 2013 Sep 8.

PMID:
24013786
18.

Signaling networks associated with AKT activation in non-small cell lung cancer (NSCLC): new insights on the role of phosphatydil-inositol-3 kinase.

Scrima M, De Marco C, Fabiani F, Franco R, Pirozzi G, Rocco G, Ravo M, Weisz A, Zoppoli P, Ceccarelli M, Botti G, Malanga D, Viglietto G.

PLoS One. 2012;7(2):e30427. doi: 10.1371/journal.pone.0030427. Epub 2012 Feb 17.

19.

Prognostic significance of twist and N-cadherin expression in NSCLC.

Hui L, Zhang S, Dong X, Tian D, Cui Z, Qiu X.

PLoS One. 2013 Apr 23;8(4):e62171. doi: 10.1371/journal.pone.0062171. Print 2013.

20.

Combined prognostic value of both RelA and IkappaB-alpha expression in human non-small cell lung cancer.

Zhang D, Jin X, Wang F, Wang S, Deng C, Gao Z, Guo C.

Ann Surg Oncol. 2007 Dec;14(12):3581-92. Epub 2007 Sep 27.

PMID:
17899287
Items per page

Supplemental Content

Write to the Help Desk